Evidence map›Paper›PMID 34224156›Full record

ArticlePhotochemistry and photobiology2022

Adjuvant Photodynamic Therapy, Mediated via Topical Versus Systemic Administration of 5-Aminolevulinic Acid for Control of Murine Mammary Tumor after Surgical Resection.

Shirron Carter, Joann Miller, Gwendolyn Cramer, Min Yuan, Stacy Guzman, Mary E Putt, Keith A Cengel, Gary M Freedman, Theresa M Busch

Open access · greenAbstract read
In one paragraph

Article in Photochemistry and photobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shirron CarterDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1595-271X
Joann MillerDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gwendolyn CramerDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1141-3391
Min YuanDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Stacy GuzmanDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mary E PuttDepartment of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Keith A CengelDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gary M FreedmanDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Theresa M BuschDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · US

Funding

TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8M
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune responseR01CA236362 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M · 2019 to 2023
$2.2M
Treating high grade intraepithelial lesions of the anus with photodynamic therapyR21CA223366 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BEN-JOSEF, EDGAR, BUSCH, THERESA M · 2018 to 2019
$380k
NCI NIH HHS P01 CA087971NCI NIH HHS R01 CA236362NCI NIH HHS R21 CA223366
6 · The paper itself

Abstract

Treatment de-escalation is sought in the management of precursor lesions of early stage breast cancer, driving the appeal of adjuvant modalities to lumpectomy that reduce toxicity and minimally detract from patient quality of life. We investigate photodynamic therapy (PDT), with the photosensitizing prodrug, 5-aminolevulinic acid (ALA), as adjuvant therapy to complete resection of murine mammary tumor (propagated from TUBO cells). ALA was delivered either systemically (oral, 250 mg kg

Indexed as

Breast NeoplasmsPhotochemotherapyAdministration, TopicalAminolevulinic AcidAnimalsFemaleHumansMicePhotosensitizing AgentsQuality of LifeAminolevulinic AcidPhotosensitizing Agents

Identifiers

PMID34224156
PMCPMC9682898
OpenAlexW3182267442

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.